Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03865381 · ClinicalTrials.gov registry record · NA
Onduo Virtual Diabetes Clinic Study
A NA study of Diabetes Mellitus, Type 2, sponsored by Verily Life Sciences.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT03865381: Completed NA study of Diabetes Mellitus, Type 2, sponsored by Verily Life Sciences.
NCT03865381 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by Verily Life Sciences. The registered enrollment target is 60 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03865381, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by Verily Life Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective, single arm study designed to evaluate the change in hemoglobin A1c after 4 months of participation in the Onduo Virtual Diabetes Clinic (VDC) in individuals with Type 2 diabetes and suboptimal glycemic control.
Primary Outcome
Mean change in hemoglobin A1c from enrollment to 4 months
Conditions Studied
Interventions
- DEVICE Onduo App
Study Locations (2)
California
- Palo Alto Medical Foundation - Palo Alto
Pennsylvania
- Premier Medical Associates - Monroeville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-02-08 |
| Est. Completion | 2020-10-15 |
| Phase | NA |
What the finished NCT03865381 record still lists
NCT03865381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Onduo App is the first listed.
NCT03865381 reports a single indexed study location in California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03865381 about?
NCT03865381 is a clinical study titled "Onduo Virtual Diabetes Clinic Study". This is a prospective, single arm study designed to evaluate the change in hemoglobin A1c after 4 months of participation in the Onduo Virtual Diabetes Clinic (VDC) in individuals with Type 2 diabetes and suboptimal glycemic control.
What is the current status of trial NCT03865381?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2019-02-08. Estimated completion is 2020-10-15.
What conditions does trial NCT03865381 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT03865381?
The interventions under investigation include: Onduo App (DEVICE).
Who is sponsoring clinical trial NCT03865381?
This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03865381 being conducted?
This trial has 2 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03865381's enrollment target sits among peer trials
60 246th of 348 higher than 98 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI